



## Advanced Control Formulary® Change Summary Report Effective 01-01-2023

This report highlights all changes (additions, deletions and removals) to the CVS Caremark® Advanced Control Formulary.

### ADDITIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Brand Agents:</b>			
<b>Adbry</b> (tralokinumab-ldrm) subcutaneous solution for injection	Topical/ Dermatology/ Atopic Dermatitis/ Injectable	Adbry is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.	To provide an additional injectable option for the treatment of atopic dermatitis.
<b>Aimovig</b> (ereenumab-aooe) subcutaneous solution for injection	Central Nervous System/ Migraine/ Monoclonal Antibodies	Aimovig is indicated for the preventive treatment of migraine in adults.	To provide an additional monoclonal antibody option for the preventive treatment of migraine.
<b>Aklief</b> (trifarotene) topical cream	Topical/ Dermatology/ Acne/ Topical	Aklief cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.	To provide an additional topical option for the treatment of acne.
<b>Alprolix</b> (coagulation factor IX- recombinant, Fc fusion protein) intravenous solution for injection	Hematologic/ Hemophilia B Agents	Alprolix is indicated for adults and children with hemophilia B (congenital Factor IX deficiency) for: <ul style="list-style-type: none"><li>• On-demand treatment and control of bleeding episodes.</li><li>• Perioperative management of bleeding.</li><li>• Routine prophylaxis to reduce the frequency of bleeding episodes.</li></ul>	To provide an additional option for the treatment of hemophilia B.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Arazlo</b> (tazarotene) topical lotion	Topical/ Dermatology/ Acne/ Topical	Arazlo lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.	To provide an additional topical option for the treatment of acne.
<b>Cibinqo</b> (abrocitinib) oral tablet	Topical/ Dermatology/ Atopic Dermatitis/ Oral	Cibinqo is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.	To provide an additional oral option for the treatment of atopic dermatitis.
<b>Combipatch</b> (estradiol-norethindrone) transdermal patch	Endocrine and Metabolic/ Menopausal Symptom Agents/ Transdermal	Combipatch is indicated in a woman with a uterus for: <ul style="list-style-type: none"> <li>• Treatment of moderate-to-severe vasomotor symptoms due to menopause.</li> <li>• Treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause.</li> <li>• Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.</li> </ul>	To provide an additional transdermal option for treatment of hypoestrogenism and menopausal symptoms.
<b>Doptelet</b> (avatrombopag) oral tablet	Hematologic/ Thrombocytopenia Agents	Doptelet is indicated for: <ul style="list-style-type: none"> <li>• The treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.</li> <li>• The treatment of thrombocytopenia in adult patients with chronic immune</li> </ul>	To provide an additional option for the treatment of thrombocytopenia.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		thrombocytopenia who have had an insufficient response to a previous treatment.	
<b>Endari</b> (L-glutamine) powder for oral solution	Hematologic/ Sickle Cell Disease	Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.	To provide an option for the treatment of sickle cell anemia.
<b>Fensolvi</b> (leuprolide acetate) subcutaneous injection kit	Endocrine and Metabolic/ Central Precocious Puberty	Fensolvi is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty.	To provide an additional option for the treatment of central precocious puberty.
<b>Gavreto</b> (pralsetinib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Gavreto is indicated for: <ul style="list-style-type: none"> <li>• The treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).</li> <li>• The treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy.</li> <li>• The treatment of adult and pediatric patient 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.</li> </ul>	To provide an additional kinase inhibitor option for the treatment of NSCLC and thyroid cancer.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Ilaris</b> (canakinumab) subcutaneous solution for injection	Immunologic Agents/ Immunomodulators/ Miscellaneous	Ilaris is indicated for: <ul style="list-style-type: none"> <li>• The treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older, including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).</li> <li>• The treatment of tumor necrosis factor (TNF) receptor associated periodic syndrome (TRAPS) in adult and pediatric patients.</li> <li>• The treatment of hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/mevalonate kinase deficiency (MKD) in adult and pediatric patients.</li> <li>• The treatment of Familial Mediterranean fever (FMF) in adult and pediatric patients.</li> <li>• The treatment of active Still's disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.</li> </ul>	To provide an interleukin-1B blocker option for the treatment of CAPS, TRAPS, HIDS/MKD, FMF, and Still's disease.
<b>Ilumya</b> (tildrakizumab-asmn) subcutaneous solution for injection	Immunologic Agents/ Autoimmune Agents (Physician-Administered)	Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.	To provide an additional option for the treatment of plaque psoriasis.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Inlyta</b> (axitinib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Inlyta is indicated: <ul style="list-style-type: none"> <li>In combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma (RCC).</li> <li>In combination with pembrolizumab for the first-line treatment of patients with advanced RCC.</li> <li>As a single agent for the second-line treatment of advanced RCC after failure of one prior systemic therapy.</li> </ul>	To provide an additional kinase inhibitor option for the treatment of RCC.
<b>Jentadueto</b> (linagliptin-metformin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor/ Biguanide Combinations	Jentadueto is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	To provide an additional DPP-4 inhibitor/biguanide combination option for the treatment of type 2 diabetes.
<b>Jentadueto XR</b> (linagliptin-metformin ext-rel) oral extended-release tablet	Endocrine and Metabolic/ Antidiabetics/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor/ Biguanide Combinations	Jentadueto XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	To provide an additional DPP-4 inhibitor/biguanide combination option for the treatment of type 2 diabetes.
<b>Lenvima</b> (lenvatinib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Lenvima is indicated for: <ul style="list-style-type: none"> <li>The treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).</li> </ul>	To provide an additional kinase inhibitor option for the treatment of DTC, RCC, HCC, and EC.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> <li>In combination with pembrolizumab, the first-line treatment of adult patients with advanced RCC.</li> <li>The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).</li> <li>In combination with pembrolizumab, the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.</li> </ul>	
<b>Menopur</b> (menotropins) subcutaneous solution for injection	Endocrine and Metabolic/ Fertility Regulators/ Ovulation Stimulants, Gonadotropins	Menopur is indicated for the development of multiple follicles and pregnancy in ovulatory women as part of an assisted reproductive technology cycle.	To provide an additional gonadotropin option for the treatment of infertility.
<b>Myfembree</b> (relugolix- estradiol-norethindrone acetate) oral tablet	Endocrine and Metabolic/ Endometriosis	Myfembree is indicated for: <ul style="list-style-type: none"> <li>The management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.</li> <li>The management of moderate-to-severe pain associated with</li> </ul>	To provide an additional option for the treatment of endometriosis.  Note: Myfembree remains a preferred option to manage heavy menstrual bleeding associated with uterine fibroids.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		endometriosis in pre-menopausal women.	
<b>Nexavar</b> (sorafenib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Nexavar is indicated for: <ul style="list-style-type: none"> <li>• The treatment of patients with unresectable HCC.</li> <li>• The treatment of patients with advanced RCC.</li> <li>• The treatment of patients with locally recurrent or metastatic, progressive, DTC that is refractory to radioactive iodine treatment.</li> </ul>	To provide an additional kinase inhibitor option for the treatment of HCC, RCC and DTC.
<b>Omnipod 5 G6</b> (insulin management system) insulin infusion pump	Endocrine and Metabolic/ Antidiabetics/ Supplies	Omnipod 5 is used to allow continuous subcutaneous basal insulin infusion and on-demand bolus dosing in those with insulin-dependent diabetes.	To provide an additional continuous/basal and on-demand/bolus insulin delivery option in insulin-dependent diabetes.
<b>Qulipta</b> (atogepant) oral tablet	Central Nervous System/ Migraine/ Miscellaneous Oral Agents	Qulipta is indicated for the preventive treatment of episodic migraine in adults.	To provide an additional option for the preventive treatment of migraine.
<b>Retevmo</b> (selpercatinib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Retevmo is indicated for: <ul style="list-style-type: none"> <li>• The treatment of adult patients with metastatic RET fusion-positive NSCLC.</li> <li>• The treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.</li> </ul>	To provide an additional kinase inhibitor option for the treatment of NSCLC and thyroid cancer.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> <li>The treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.</li> </ul>	
<b>Rytary</b> (carbidopa-levodopa) oral extended-release capsule	Central Nervous System/ Antiparkinsonian Agents	Rytary is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.	To provide an additional option for the treatment of Parkinson's disease.
<b>Siklos</b> (hydroxyurea) oral tablet	Hematologic/ Sickle Cell Disease	Siklos is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.	To provide an option for the treatment of sickle cell anemia.
<b>Skyrizi Intravenous</b> (risankizumab-rzaa) intravenous solution for injection	Immunologic Agents/ Autoimmune Agents (Physician-Administered)	Skyrizi Intravenous is indicated for the treatment of moderately-to-severely active Crohn's disease in adults.	To provide an additional option for the treatment of Crohn's Disease.
<b>Skyrizi Subcutaneous</b> (risankizumab-rzaa) subcutaneous solution for injection	Immunologic Agents/ Autoimmune Agents (Self-Administered)/Crohn's Disease	Skyrizi Subcutaneous is indicated for: <ul style="list-style-type: none"> <li>The treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.</li> </ul>	To provide an additional option for the treatment of Crohn's Disease.  Note: Skyrizi remains preferred for: <ul style="list-style-type: none"> <li>Psoriasis</li> <li>Psoriatic arthritis</li> </ul>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.



Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> <li>The treatment of active psoriatic arthritis in adults.</li> <li>The treatment of moderately-to-severely active Crohn's disease in adults.</li> </ul>	
<b>Tezspire</b> (tezepelumab-ekko) subcutaneous solution for injection	Respiratory/ Severe Asthma Agents	Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients 12 years of age and older with severe asthma.	To provide an additional option for the treatment of severe asthma.
<b>Tradjenta</b> (linagliptin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	Tradjenta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	To provide a DPP-4 inhibitor option for the treatment of type 2 diabetes.
<b>Twynéo</b> (tretinoin- benzoyl peroxide) 0.1%-3% topical cream	Topical/ Dermatology/ Acne/ Topical	Twynéo cream is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.	To provide an additional topical option for the treatment of acne.
<b>Winlevi</b> (clascoterone) topical cream	Topical/ Dermatology/ Acne/ Topical	Winlevi cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.	To provide an additional topical option for the treatment of acne.
<b>Xyntha</b> (antihemophilic factor-recombinant) intravenous solution for injection	Hematologic/ Hemophilia A Agents	Xyntha is indicated for adults and children with hemophilia A (congenital Factor VIII deficiency) for: <ul style="list-style-type: none"> <li>On-demand treatment and control of bleeding episodes.</li> <li>Perioperative management of bleeding.</li> </ul>	To provide an additional option for the treatment of hemophilia A.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> <li>Routine prophylaxis to reduce the frequency of bleeding episodes.</li> </ul>	
<b>Zydelig</b> (idelalisib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.	To provide an additional kinase inhibitor option for the treatment of CLL.
<b>Generic Agents:</b>			
<b>amiodarone</b> oral tablet, intravenous solution for injection	Cardiovascular/ Antiarrhythmics	Amiodarone is indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated.	To provide an additional antiarrhythmic option.
<b>amphetamine-dextroamphetamine mixed salts ext-rel</b> oral extended-release capsule	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Amphetamine-dextroamphetamine mixed salts is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).	To provide an additional option for the treatment of ADHD.
<b>bortezomib</b> subcutaneous/ intravenous solution for injection	Antineoplastic Agents/ Multiple Myeloma/ Proteasome Inhibitors	Bortezomib is indicated for: <ul style="list-style-type: none"> <li>The treatment of adult patients with multiple myeloma.</li> <li>The treatment of adult patients with mantle cell lymphoma.</li> </ul>	To provide a generic proteasome inhibitor option.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>mesalamine 800mg delayed-rel</b> oral delayed-release tablet	Gastrointestinal/ Inflammatory Bowel Disease/ Oral Agents	Mesalamine is indicated for the treatment of moderately active ulcerative colitis (UC) in adults.	To provide an additional option for the treatment of moderately active UC.
<b>methylphenidate ext-rel</b> oral extended-release tablet	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Methylphenidate ext-rel is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.	To provide an additional option for the treatment of ADHD.
<b>naloxone</b> nasal spray	Central Nervous System/ Psychotherapeutic Miscellaneous/ Opioid Antagonists	Naloxone nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.	To provide an additional option for the emergency treatment of known or suspected opioid overdose.
<b>pemetrexed</b> intravenous solution for injection	Antineoplastic Agents/ Antimetabolites	Pemetrexed is indicated: <ul style="list-style-type: none"> <li>• In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic NSCLC, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.</li> <li>• In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.</li> <li>• As a single agent for the maintenance treatment of patients with locally</li> </ul>	To provide a generic option for NSCLC and mesothelioma.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. <ul style="list-style-type: none"> <li>As a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.</li> <li>In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.</li> </ul>	
<b>pirfenidone</b> oral tablet	Respiratory/ Pulmonary Fibrosis Agents	Pirfenidone tablets are indicated for the treatment of idiopathic pulmonary fibrosis (IPF).	To provide a generic option for the treatment of IPF.

**DELETIONS:**

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Brand Agents:</b>			
<b>Narcan</b> (naloxone) nasal spray	Central Nervous System/ Psychotherapeutic	Narcan nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as	Availability of generic opioid antagonist options.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

## Advanced Control Formulary® Change Summary Report Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
	Miscellaneous/ Opioid Antagonists	manifested by respiratory and/or central nervous system depression.	Preferred option on the Advanced Control Formulary is naloxone.
<b>Velcade</b> (bortezomib) subcutaneous/ intravenous solution for injection	Antineoplastic Agents/ Multiple Myeloma/ Proteasome Inhibitors	Velcade is indicated for: <ul style="list-style-type: none"> <li>The treatment of adult patients with multiple myeloma.</li> <li>The treatment of adult patients with mantle cell lymphoma.</li> </ul>	Availability of additional proteasome inhibitor options.  Preferred options on the Advanced Control Formulary include bortezomib and Ninlaro (ixazomib).

### REMOVALS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Brand Agents:</b>			
<b>Adderall XR</b> (amphetamine-dextroamphetamine mixed salts ext-rel) oral extended-release capsule	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Adderall XR is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).	Availability of additional options for the treatment of ADHD.  Preferred options on the Advanced Control Formulary include amphetamine-dextroamphetamine mixed salts ext-rel, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel, Azstarys (serdexmethylphenidate-dexmethylphenidate), Jornay PM (methylphenidate ext-rel), Mydayis (amphetamine-dextroamphetamine mixed salts ext-rel), and Vyvanse (lisdexamfetamine).
<b>Advair HFA</b> (fluticasone-salmeterol) oral inhaler	Respiratory/ Steroid/ Beta Agonist Combinations	Advair HFA is indicated for treatment of asthma in adult and adolescent patients 12 years of age and older.	Availability of additional steroid/beta agonist combination options for the treatment of asthma.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
			Preferred options on the Advanced Control Formulary include Advair Diskus (fluticasone-salmeterol), Breo Ellipta (fluticasone-vilanterol), and Symbicort (budesonide-formoterol).
<b>Alimta</b> (pemetrexed) intravenous solution for injection	Antineoplastic Agents/ Antimetabolites	Alimta is indicated: <ul style="list-style-type: none"> <li>• In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic NSCLC, with no EGFR or ALK genomic tumor aberrations.</li> <li>• In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.</li> <li>• As a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.</li> <li>• As a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.</li> <li>• In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are</li> </ul>	Availability of a generic option for NSCLC and mesothelioma.  Preferred option on the Advanced Control Formulary is pemetrexed.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

## Advanced Control Formulary® Change Summary Report Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		otherwise not candidates for curative surgery.	
<b>Arcalyst</b> (rilonacept) subcutaneous solution for injection	Analgesics/ Interleukin-1 Blockers	<p>Arcalyst is indicated for:</p> <ul style="list-style-type: none"> <li>• The treatment of CAPS, including FCAS, and MWS in adults and pediatric patients 12 years of age and older.</li> <li>• The maintenance of remission of deficiency of interleukin-1 receptor antagonist (DIRA) in adults and pediatric patients weighing at least 10kg.</li> <li>• The treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years of age and older.</li> </ul>	<p>Availability of additional option for CAPS, DIRA and RP.</p> <p>Preferred option on the Advanced Control Formulary is Ilaris (canakinumab).</p>
<b>Arnuity Ellipta</b> (fluticasone furoate) oral inhaler	Respiratory/ Steroid Inhalants	Arnuity Ellipta is indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.	<p>Availability of additional oral steroid inhalant options.</p> <p>Preferred options on the Advanced Control Formulary include Flovent HFA (fluticasone) and Pulmicort Flexhaler (budesonide).</p>
<b>Asacol HD</b> (mesalamine 800mg delayed-rel) oral delayed-release tablet	Gastrointestinal/ Inflammatory Bowel Disease/ Oral Agents	Asacol HD is indicated for the treatment of moderately active ulcerative colitis (UC) in adults.	<p>Availability of additional options for the treatment of UC.</p> <p>Preferred options on the Advanced Control Formulary include balsalazide, mesalamine delayed-rel, mesalamine ext-rel, sulfasalazine, sulfasalazine delayed-rel.</p>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

## Advanced Control Formulary® Change Summary Report Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Benefix</b> (coagulation factor IX-recombinant) intravenous solution for injection	Hematologic/ Hemophilia B Agents	Benefix is indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for: <ul style="list-style-type: none"> <li>• On-demand treatment and control of bleeding episodes.</li> <li>• Perioperative management of bleeding.</li> <li>• Routine prophylaxis to reduce the frequency of bleeding episodes.</li> </ul>	Availability of additional options for hemophilia B.  Preferred options on the Advanced Control Formulary include Alprolix (coagulation factor IX- recombinant, Fc fusion protein) and Rebinyn (coagulation factor IX- recombinant glycopegylated).
<b>Concerta</b> (methylphenidate ext-rel) oral extended-release tablet	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.	Availability of additional options for the treatment of ADHD.  Preferred options on the Advanced Control Formulary include amphetamine-dextroamphetamine mixed salts ext-rel, dexamethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel, Azstarys (serdexmethylphenidate-dexamethylphenidate), Jornay PM (methylphenidate ext-rel), Mydayis (amphetamine-dextroamphetamine mixed salts ext-rel), and Vyvanse (lisdexamfetamine).
<b>Esbriet</b> (pirfenidone) oral capsule, oral tablet	Respiratory/ Pulmonary Fibrosis Agents	Esbriet is indicated for the treatment of IPF.	Availability of additional options for IPF.  Preferred options on the Advanced Control Formulary include pirfenidone and Ofev (nintedanib).
<b>Firazyr</b> (icatibant acetate) subcutaneous solution for injection	Immunologic Agents/ Hereditary Angioedema	Firazyr is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.	Availability of additional options for acute attacks of HAE.  Preferred options on the Advanced Control Formulary include icatibant and Ruconest (C1 esterase inhibitor, recombinant).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.



## Advanced Control Formulary® Change Summary Report Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Flovent Diskus</b> (fluticasone propionate) oral inhaler	Respiratory/ Steroid Inhalants	Flovent Diskus is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older.	Availability of additional oral steroid inhalant options.  Preferred options on the Advanced Control Formulary include Flovent HFA (fluticasone) and Pulmicort Flexhaler (budesonide).
<b>Ixinity</b> (coagulation factor IX-recombinant) intravenous solution for injection	Hematologic/ Hemophilia B Agents	Ixinity is indicated for the treatment of: <ul style="list-style-type: none"> <li>• Adults and children 12 years of age and older with hemophilia B for: <ul style="list-style-type: none"> <li>○ On-demand treatment and control of bleeding episodes.</li> <li>○ Perioperative management.</li> </ul> </li> <li>• Adults with hemophilia B for: <ul style="list-style-type: none"> <li>○ Routine prophylaxis to reduce the frequency of bleeding episodes.</li> </ul> </li> </ul>	Availability of additional options for hemophilia B.  Preferred options on the Advanced Control Formulary include Alprolix (coagulation factor IX- recombinant, Fc fusion protein) and Rebinyn (coagulation factor IX-recombinant glycopegylated).
<b>Janumet</b> (sitagliptin-metformin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor/ Biguanide Combinations	Janumet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	Availability of additional DPP-4 inhibitor/biguanide combination options for type 2 diabetes mellitus.  Preferred options on the Advanced Control Formulary include Jentadueto (linagliptin-metformin) and Jentadueto XR (linagliptin-metformin ext-rel).
<b>Janumet XR</b> (sitagliptin-metformin ext-rel) oral extended-release tablet	Endocrine and Metabolic/ Antidiabetics/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor/ Biguanide Combinations	Janumet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	Availability of additional DPP-4 inhibitor biguanide combination options for type 2 diabetes mellitus.  Preferred options on the Advanced Control Formulary include Jentadueto (linagliptin-metformin) and Jentadueto XR (linagliptin-metformin ext-rel).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

## Advanced Control Formulary® Change Summary Report Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Januvia</b> (sitagliptin) oral tablet	Endocrine and Metabolic/ Antidiabetics/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	Januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	Availability of an additional DPP-4 inhibitor option for type 2 diabetes mellitus.  Preferred option on the Advanced Control Formulary is Tradjenta (linagliptin).
<b>Multaq</b> (dronedarone) oral tablet	Cardiovascular/ Antiarrhythmics	Multaq is indicated to reduce the risk of hospitalization from atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF.	Availability of an additional antiarrhythmic option for AF.  Preferred option on the Advanced Control Formulary is amiodarone.
<b>Nexterone</b> (amiodarone HCl) intravenous solution for injection	Cardiovascular/ Antiarrhythmics	Nexterone is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.	Availability of an additional antiarrhythmic option for ventricular fibrillation.  Preferred option on the Advanced Control Formulary is amiodarone.
<b>Nityr</b> (nitisinone) oral tablet	Endocrine and Metabolic/ Hereditary Tyrosinemia Type 1 Agents	Nityr is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.	Availability of an additional option for HT-1.  Preferred option on the Advanced Control Formulary is Orfadin (nitisinone).
<b>Nucala Lyophilized</b> (mepolizumab) lyophilized powder for reconstitution	Respiratory/ Severe Asthma Agents	Nucala is indicated for: <ul style="list-style-type: none"> <li>• The add-on maintenance treatment of adult and pediatric patients 6 years of age and older with severe asthma and with an eosinophilic phenotype.</li> <li>• The add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of</li> </ul>	Availability of additional options for maintenance treatment of severe asthma, EGPA and HES.  Preferred options on the Advanced Control Formulary include Dupixent (dupilumab), Fasenra (benralizumab), Nucala [except lyophilized powder] (mepolizumab), Tezspire (tezepelumab-ekko), and Xolair (omalizumab).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		age and older with inadequate response to nasal corticosteroids. <ul style="list-style-type: none"> <li>The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).</li> <li>The treatment of adult and pediatric patients 12 years of age and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.</li> </ul>	
<b>Nucynta</b> (tapentadol) oral tablet	Analgesics/ Opioid Analgesics	Nucynta is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults.	Availability of generic opioid options for the management of severe acute pain.  Preferred options on the Advanced Control Formulary include hydromorphone, morphine, and oxycodone.
<b>Nucynta ER</b> (tapentadol ext-rel) oral extended-release tablet	Analgesics/ Opioid Analgesics	Nucynta ER is indicated for the management of: <ul style="list-style-type: none"> <li>Pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</li> <li>Neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</li> </ul>	Availability of additional opioid options for the management of severe chronic pain and DPN.  Preferred options on the Advanced Control Formulary include fentanyl transdermal, hydrocodone ext-rel, methadone, morphine ext-rel, and Xtampza ER (oxycodone ext-rel).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

## Advanced Control Formulary® Change Summary Report Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>QVAR Redihaler</b> (beclomethasone dipropionate) oral inhaler	Respiratory/ Steroid Inhalants	QVAR Redihaler is indicated in the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older.	Availability of additional oral steroid inhalant options.  Preferred options on the Advanced Control Formulary include Flovent HFA (fluticasone) and Pulmicort Flexhaler (budesonide).
<b>Rixubis</b> (coagulation factor IX-recombinant) intravenous solution for injection	Hematologic/ Hemophilia B Agents	Rixubis is indicated in adults and children with hemophilia B for: <ul style="list-style-type: none"> <li>• On-demand treatment and control of bleeding episodes.</li> <li>• Perioperative management of bleeding.</li> <li>• Routine prophylaxis to reduce the frequency of bleeding episodes.</li> </ul>	Availability of additional options for hemophilia B.  Preferred options on the Advanced Control Formulary include Alprolix (coagulation factor IX- recombinant, Fc fusion protein) and Rebinyn (coagulation factor IX- recombinant glycopegylated).
<b>Rubraca</b> (rucaparib) oral tablet	Antineoplastic Agents/ Miscellaneous	Rubraca is indicated for: <ul style="list-style-type: none"> <li>• The maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.</li> <li>• The treatment of adult patients with a deleterious <i>BRCA</i> mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.</li> </ul>	Availability of additional options for recurrent epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer and mCRPC.  Preferred options on the Advanced Control Formulary include Lynparza (olaparib) and Zejula (niraparib).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.



Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Subsys</b> (fentanyl) sublingual spray	Analgesics/ Opioid Analgesics	Subsys is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.	Availability of a generic option for the management of breakthrough pain in adult cancer patients.  Preferred option on the Advanced Control Formulary is fentanyl transmucosal.
<b>Sutent</b> (sunitinib) oral capsule	Antineoplastic Agents/ Kinase Inhibitors	Sutent is indicated for: <ul style="list-style-type: none"> <li>• The treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.</li> <li>• The treatment of adult patients with advanced RCC.</li> <li>• The adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.</li> <li>• The treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in adult patients with unresectable locally advanced or metastatic disease.</li> </ul>	Availability of additional kinase inhibitor options for the treatment of GIST, RCC and pancreatic neuroendocrine tumors.  Preferred options on the Advanced Control Formulary include sunitinib, Cabometyx (cabozantinib), Inlyta (axitinib), Lenvima (lenvatinib) and Nexavar (sorafenib).
<b>Toviaz</b> (fesoterodine fumarate) oral extended-release tablet	Genitourinary/ Urinary Antispasmodics	Toviaz is indicated for: <ul style="list-style-type: none"> <li>• The treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.</li> </ul>	Availability of additional urinary antispasmodics for OAB and NDO.  Preferred options on the Advanced Control Formulary include darifenacin ext-rel, oxybutynin ext-rel, solifenacin, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, and Gemtesa (vibegron).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> <li>The treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25kg.</li> </ul>	
<b>Votrient</b> (pazopanib) oral tablet	Antineoplastic Agents/ Kinase Inhibitors	Votrient is indicated for: <ul style="list-style-type: none"> <li>The treatment of adults with advanced RCC.</li> <li>The treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.</li> </ul>	Availability of additional kinase inhibitor options for the treatment of RCC and STS.  Preferred options on the Advanced Control Formulary include sunitinib, Cabometyx (cabozantinib), Inlyta (axitinib), Lenvima (lenvatinib) and Nexavar (sorafenib).
<b>Generic Agents:</b>			
<b>diclofenac potassium 25mg</b> oral capsule	Analgesics/ NSAIDs	Diclofenac potassium is indicated for relief of mild to moderate acute pain in adult and pediatric patients 12 years of age and older.	Availability of additional non-steroidal anti-inflammatory drug (NSAID) options for relief of mild to moderate acute pain.  Preferred options on the Advanced Control Formulary include diclofenac sodium, ibuprofen, meloxicam tablet, and naproxen (except naproxen CR or naproxen suspension).
<b>diclofenac sodium solution 2%</b> topical solution	Analgesics/ NSAIDs/ Topical	Diclofenac sodium solution is indicated for the treatment of the pain of osteoarthritis of the knee(s).	Availability of additional NSAID options for relief of mild to moderate acute pain.  Preferred options on the Advanced Control Formulary include diclofenac sodium, diclofenac sodium gel 1%, diclofenac sodium solution 1.5%, ibuprofen, meloxicam tablet, and naproxen (except naproxen CR or naproxen suspension).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

**OTHER:**

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Brand Agents:</b>			
<b>Rinvoq</b> (upadacitinib) oral extended-release tablet	Immunologic Agents/ Autoimmune Agents (Self-Administered)/ Ulcerative Colitis	Rinvoq is indicated for the treatment of: <ul style="list-style-type: none"> <li>• Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.</li> <li>• Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• Adults with active ankylosing spondylitis who have had an inadequate response</li> </ul>	Now first line for ulcerative colitis. No longer requires a prior failure of Humira (adalimumab).  Note: Rinvoq remains preferred for: <ul style="list-style-type: none"> <li>• Atopic dermatitis</li> <li>• Psoriatic arthritis</li> <li>• Rheumatoid arthritis</li> <li>• Ankylosing spondylitis</li> </ul>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		or intolerance to one or more TNF blockers.	
<b>Xeljanz</b> (tofacitinib) oral tablet, oral solution	Immunologic Agents/ Autoimmune Agents (Self-Administered)/ Ulcerative Colitis	Xeljanz is indicated for: <ul style="list-style-type: none"> <li>• The treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• The treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• The treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• The treatment of adult patients with moderately to severely active ulcerative colitis, who have an inadequate response or who are intolerant to one or more TNF blockers.</li> <li>• The treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older.</li> </ul>	Now first line for ulcerative colitis. No longer requires a prior failure of Humira (adalimumab).  Note: Xeljanz remains excluded for ankylosing spondylitis and psoriatic arthritis. Xeljanz remains preferred for rheumatoid arthritis.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.



Advanced Control Formulary®  
 Change Summary Report  
 Effective 01-01-2023

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
<b>Xeljanz XR</b> (tofacitinib) oral extended-release tablet	Immunologic Agents/ Autoimmune Agents (Self-Administered)/ Ulcerative Colitis	Xeljanz XR is indicated for: <ul style="list-style-type: none"> <li>• The treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• The treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• The treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.</li> <li>• The treatment of adult patients with moderately to severely active ulcerative colitis, who have an inadequate response or who are intolerant to TNF blockers.</li> </ul>	Now first line for ulcerative colitis. No longer requires a prior failure of Humira (adalimumab).  Note: Xeljanz remains excluded for ankylosing spondylitis and psoriatic arthritis. Xeljanz remains preferred for rheumatoid arthritis.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.